Evidence map›Paper›PMID 25759096›Full record

ReviewVirology2015

Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.

Edward M Kennedy, Bryan R Cullen

Open access · greenAbstract readReview
In one paragraph

Review in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.Molecular therapy. Methods & clinical development · 2020
    Review
  7. Review
  8. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019
    Review
  9. Article
  10. The Impact of CRISPR-Cas System on Antiviral Therapy.Advanced pharmaceutical bulletin · 2018
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Eradication Strategies for Chronic Hepatitis B Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Review
  16. Article
  17. Genome-editing Technologies for Gene and Cell Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  18. Review
  19. Article
  20. Stepping toward therapeutic CRISPR.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Edward M KennedyDepartment of Molecular Genetics and Microbiology and Center for Virology, Duke University Medical Center, Durham, NC, USA.
Bryan R CullenDepartment of Molecular Genetics and Microbiology and Center for Virology, Duke University Medical Center, Durham, NC, USA. Electronic address: bryan.cullen@duke.edu.
Duke Medical Center · USDuke University · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Role and mechanism of action of Gamma herpesvirus microRNAsR01AI067968 · NIAID · DUKE UNIVERSITY · PI CULLEN, BRYAN R. · 2006 to 2016
$3.6M
HIV-1: microRNA interactionsR01DA030086 · NIDA · DUKE UNIVERSITY · PI CULLEN, BRYAN R. · 2010 to 2014
$1.9M
Regulation of lytic and latent infection by HSV-1 encoded miRNAsR01AI097376 · NIAID · UNIVERSITY OF FLORIDA · PI BLOOM, DAVID C. · 2012 to 2016
$1.9M
Reconstitution of a protective antiviral RNAi response in somatic human cellsR21AI113098 · NIAID · DUKE UNIVERSITY · PI CULLEN, BRYAN R. · 2014 to 2015
$434k
NIAID NIH HHS P30 AI064518NIAID NIH HHS P30-AI064518NIAID NIH HHS R01 AI067968NIAID NIH HHS R01-AI067968NIAID NIH HHS R01 AI097376NIAID NIH HHS R01-AI097376NIAID NIH HHS R21 AI113098NIAID NIH HHS R21-AI113098ANDNIDA NIH HHS R01 DA030086
6 · The paper itself

Abstract

CRISPR/Cas systems mediate bacterial adaptive immune responses that evolved to protect bacteria from bacteriophage and other horizontally transmitted genetic elements. Several CRISPR/Cas systems exist but the simplest variant, referred to as Type II, has a single effector DNA endonuclease, called Cas9, which is guided to its viral DNA target by two small RNAs, the crRNA and the tracrRNA. Initial efforts to adapt the CRISPR/Cas system for DNA editing in mammalian cells, which focused on the Cas9 protein from Streptococcus pyogenes (Spy), demonstrated that Spy Cas9 can be directed to DNA targets in mammalian cells by tracrRNA:crRNA fusion transcripts called single guide RNAs (sgRNA). Upon binding, Cas9 induces DNA cleavage leading to mutagenesis as a result of error prone non-homologous end joining (NHEJ). Recently, the Spy Cas9 system has been adapted for high throughput screening of genes in human cells for their relevance to a particular phenotype and, more generally, for the targeted inactivation of specific genes, in cell lines and in vivo in a number of model organisms. The latter aim seems likely to be greatly enhanced by the recent development of Cas9 proteins from bacterial species such as Neisseria meningitidis and Staphyloccus aureus that are small enough to be expressed using adeno-associated (AAV)-based vectors that can be readily prepared at very high titers. The evolving Cas9-based DNA editing systems therefore appear likely to not only impact virology by allowing researchers to screen for human genes that affect the replication of pathogenic human viruses of all types but also to derive clonal human cell lines that lack individual gene products that either facilitate or restrict viral replication. Moreover, high titer AAV-based vectors offer the possibility of directly targeting DNA viruses that infect discrete sites in the human body, such as herpes simplex virus and hepatitis B virus, with the hope that the entire population of viral DNA genomes might be destroyed. In conclusion, we believe that the continued rapid evolution of CRISPR/Cas technology will soon have a major, possibly revolutionary, impact on the field of virology.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsHost-Pathogen InteractionsBacteriaBacterial ProteinsDependovirusEndodeoxyribonucleasesGenetic VectorsHumansMolecular BiologyRecombinant ProteinsBacterial ProteinsEndodeoxyribonucleasesRecombinant ProteinsAntiviral gene therapyCRISPR/CasGene editingSequence specific DNA cleavage

Identifiers

PMID25759096
PMCPMC4424069
OpenAlexW1988378555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.